Trials / Completed
CompletedNCT02575950
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 Applied in a Split-face (Left/Right) Topical Design in Adults With Moderate to Severe Acne
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of LEO 43204 in adults with moderate to severe acne.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO43204 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2015-10-15
- Last updated
- 2025-03-06
- Results posted
- 2019-02-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02575950. Inclusion in this directory is not an endorsement.